Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;54 Suppl 4(Suppl 4):S362-8.
doi: 10.1093/cid/cir987.

Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program

Nellie Wadonda-Kabondo  1 , Diane Bennett, Joep J van Oosterhout, Kundai Moyo, Mina Hosseinipour, Josh Devos, Zhiyong Zhou, John Aberle-Grasse, Thomas R Warne, Clement Mtika, Ben Chilima, Richard Banda, Olesi Pasulani, Carol Porter, Sam Phiri, Andreas Jahn, Debbie Kamwendo, Michael R Jordan, Storn Kabuluzi, Frank Chimbwandira, Mathew Kagoli, Blackson Matatiyo, Austin Demby, Chunfu Yang
Affiliations

Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program

Nellie Wadonda-Kabondo et al. Clin Infect Dis. 2012 May.

Abstract

Since 2004, the Malawi antiretroviral treatment (ART) program has provided a public health-focused system based on World Health Organization clinical staging, standardized first-line ART regimens, limited laboratory monitoring, and no patient-level monitoring of human immunodeficiency virus drug resistance (HIVDR). The Malawi Ministry of Health conducts periodic evaluations of HIVDR development in prospective cohorts at sentinel clinics. We evaluated viral load suppression, HIVDR, and factors associated with HIVDR in 4 ART sites at 12-15 months after ART initiation. More than 70% of patients initiating ART had viral suppression at 12 months. HIVDR prevalence (6.1%) after 12 months of ART was low and largely associated with baseline HIVDR. Better follow-up, removal of barriers to on-time drug pickups, and adherence education for patients 16-24 years of age may further prevent HIVDR.

PubMed Disclaimer

References

    1. The Republic of Malawi Ministry of Health. HIV and syphilis sero-survey and national HIV prevention and AIDS estimates report for 2007. 2007. Available at: http://www.huvunitmohmw.org/Main/HIVMeetingsAndHIVUnitReports. Accessed 13 April 2011.
    1. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22:1971–7. - PubMed
    1. Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr. 2006;43:436–9. - PubMed
    1. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23:697–700. - PMC - PubMed
    1. Hosseinipour MC, van Oosterhout JJG, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127–34. - PMC - PubMed

Publication types

Substances